On Friday, Humacyte Inc (HUMA) stock saw a modest uptick, ending the day at $4.47 which represents a slight increase of $0.07 or 1.59% from the prior close of $4.4. The stock opened at $4.44 and ...

If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your ...

Class Action, Consumer Services, GlobeNewswire, Law & Legal Issues | NEW YORK, Nov. 30, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law F ...

Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) has been assigned a consensus rating of “Buy” from the eight research firms ...

New York, New York-- (Newsfile Corp. - November 29, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, ...

On Monday, Humacyte Inc (HUMA) stock saw a decline, ending the day at $4.28 which represents a decrease of $-0.21 or -4.68% from the prior close of $4.49. The stock opened at $4.47 and touched a low ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Under the terms of the securities purchase agreement DURHAM, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing ...

Investors suffering losses on their Humacyte investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 215-638-4847 or by email ...

Humacyte, Inc. (NASDAQ: HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers ...

DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable ...